Modulating Fibrotic Mechanical Microenvironment for Idiopathic Pulmonary Fibrosis Therapy
- PMID: 39529565
- DOI: 10.1002/adma.202407661
Modulating Fibrotic Mechanical Microenvironment for Idiopathic Pulmonary Fibrosis Therapy
Abstract
Idiopathic pulmonary fibrosis (IPF) is exacerbated by injurious mechanical forces that destabilize the pulmonary mechanical microenvironment homeostasis, leading to alveolar dysfunction and exacerbating disease severity. However, given the inherent mechanosensitivity of fibrotic lungs, where type II alveolar epithelial cells (AEC IIs) are subjected to persistent stretching and overactivated myofibroblasts experience malignant interactions during mechanotransduction, it becomes imperative to develop effective strategies to modulate the pulmonary mechanical microenvironment. Herein, cyclo (RGDfC) peptide-decorated zeolitic imidazolate framework-8 nanoparticles (named ZDFPR NPs) are constructed to target and repair the aberrant mechanical force levels in pathological lungs. Specifically, reduces mechanical tension in AEC IIs by pH-responsive ZDFPR NPs that release zinc ions and 7, 8-dihydroxyflavone to promote alveolar repair and differentiation. Meanwhile, malignant interactions between myofibroblast contractility and extracellular matrix stiffness during mechanotransduction are disrupted by the fasudil inhibition ROCK signaling pathway. The results show that ZDFPR NPs successfully restored pulmonary mechanical homeostasis and terminated the fibrosis process in bleomycin-induced fibrotic mice. This study not only presents a promising strategy for modulating pulmonary mechanical microenvironment but also pioneers a novel avenue for IPF treatment.
Keywords: idiopathic pulmonary fibrosis; malignant interactions; mechanical force; mechanical microenvironment; mechanotransduction.
© 2024 Wiley‐VCH GmbH.
References
-
- a) L. Richeldi, H. R. Collard, M. G. Jones, Lancet 2017, 389, 1941;
-
- b) J. Snijder, J. Peraza, M. Padilla, K. Capaccione, M. M. Salvatore, Expert Rev. Respir. Med. 2019, 13, 615.
-
- a) F. J. Martinez, H. R. Collard, A. Pardo, G. Raghu, L. Richeldi, M. Selman, J. J. Swigris, H. Taniguchi, A. U. Wells, Nat. Rev. Dis. Primers 2017, 3, 17074;
-
- b) P. M. George, A. U. Wells, R. G. Jenkins, Lancet Respir. Med. 2020, 8, 807.
-
- a) B. L. Doss, M. Pan, M. Gupta, G. Grenci, R. M. Mège, C. T. Lim, M. P. Sheetz, R. Voituriez, B. Ladoux, Proc. Natl. Acad. Sci. USA 2020, 117, 12817;
MeSH terms
Substances
Grants and funding
- 2022YFE0198400/National Key Research and Development Program of China
- Project of State Key Laboratory of Natural Medicines
- SKLNMZZ202021/China Pharmaceutical University
- BK20232035/Natural Science Foundation of Jiangsu Basic Research Program-Project
- 82020108029/National Natural Science Foundation of China
LinkOut - more resources
Full Text Sources